Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02201212
Title Everolimus for Cancer With TSC1 or TSC2 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST